Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
7-thionicotinamide-adenine-dinucleotide phosphate is a synthetic analog of nicotinamide adenine dinucleotide phosphate (NADP), in which the nicotinamide moiety is replaced by thionicotinamide. It belongs to the class of (5'->5')-dinucleotides and has a molecular formula of C21H28N7O16P3S. This compound is primarily used as an experimental biochemical tool rather than as a therapeutic drug. It can act as an alternative cofactor in enzymatic reactions that normally utilize NADP(H), and it has been studied for its ability to block NAADP-induced calcium release[1][2][8]. Its mechanism involves mimicking or interfering with natural NAD(P)H-dependent processes; for example, it can be used to probe redox biochemistry or modulate calcium signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7-thionicotinamide-adenine-dinucleotide phosphate.